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Systemic autoimmune and rheumatic diseases (SAIRDs) are thought to develop due to the failure of autoimmune regulation
and tolerance. Current therapies, such as biologics, have improved the clinical results of SAIRDs; however, they are not curative
treatments. Recently, new discoveries have been made in immune tolerance and inﬂammation, such as tolerogenic dendritic cells,
regulatory T and B cells, Th 17 cells, inﬂammatory and tolerogenic cytokines, and intracellular signaling pathways. They lay the
foundation for the next generation of the therapies beyond the currently used biologic therapies. New drugs should target the core
processes involved in disease mechanisms with the aim to attain complete cure combined with safety and low costs compared to
the biologic agents. Re-establishment of autoimmune regulation and tolerance in SAIRDs by the end of the current decade should
be the ﬁnal and realistic target.
1.Introduction
Recently, several important new discoveries have been made
on both immunogenicity and autoimmune regulation and
tolerance.Immunetoleranceisnecessaryforthehomeostatic
and balanced host defense. It is important to recognize the
role of the self-antigens which should be protected (non-
dangerous) or self- and nonself-antigens which should be
eliminated (dangerous) for the induction and maintenance
of autoimmune regulation and tolerance. Immune system is
constantly in contact with numerous self-antigens including
autologous necrotic or apoptotic tissues, and it uses multiple
strategies to prevent autoimmunity [1]. The antigen-speciﬁc
or nonspeciﬁc immune tolerance can be generated primarily
in thymus or secondarily in peripheral lymphatic and
extralymphatic tissues. Various elimination mechanisms of
a u t o r e a c t i v eTc e l l sa n dBc e l l ss u c ha sp r e s e n t a t i o no f
autoantigen by antigen-presenting cells (APCs) and regula-
tion by regulatory T cells (Tregs) play a role, not only for the
central tolerance in the thymus, but also for the peripheral
toleranceinextrathymictissues,whichexertanongoingcon-
trol to avoid systemic autoimmune and rheumatic diseases
(SAIRDs). Within the thymus, T cells go through positive
and negative selection processes in anatomically diﬀerent
locations to shape the entire peripheral T-cell repertoire
when the central tolerance is established. Peripheral toler-
anceisthenproducedbyengagementofdendriticcells(DCs)
via several mechanisms, including generation and expansion
of Treg cells and regulatory cytokines [2–5].
The onset and progression of SAIRDs depends on
multiple factors, and many types of cells are involved in
the multiple pathways of the immune reaction [5–7]. In all
SAIRDs, the ultimate goal should be the re-establishment of
self-tolerance [8]. In this paper, we describe new insight and2 Clinical and Developmental Immunology
topicsrelatedtoimmuneregulationandtoleranceinSAIRDs
and their potential in the management of these diseases.
2 .T h eP a t h og e n i cR o l eo fDe n d ri ti cC ell s ,
Regulatory TandBCells,andRegulatory
CytokinesinSAIRDs
2.1. Dendritic Cells (DCs). The functional abilities of the
DCs vary depending on their subset and state of maturation.
The two major categories of DCs are the conventional
DCs (cDCs) and the plasmacytoid DCs (pDCs). They can
be further functionally classiﬁed to mature and immature
DCs. DCs for a heterogeneous group of cells, which play
an important role in immunogenicity but also in the
maintenance of immunotolerance, including their eﬀects on
the induction of antigen-speciﬁc T cell responses resulting in
anergy, apoptotic deletion, or formation of Tregs [9]. Tolero-
genic DCs populations have been generated as experimental
therapeutic tools, which have been used with some success
in murine disease models [10]. However, direct evidence
implicating a particular DC subset in the breach of self-
tolerance leading to SAIRDs is lacking although some novel
murine experimental arthritis models allow delineation of
early, preclinical events leading to the loss of self-tolerance
[11, 12].
2.2. Conventional Dendritic Cells (cDCs). CDCs are detected
in blood, skin, secondary lymph nodes, spleen, and inﬂam-
matory synovitis [1, 4, 7, 13]. They are subdivided into two
categories, migratory DCs and resident DCs, for example,
Langerhans cells in the skin and mucosal membranes. In
addition, there are other types of cDC that are derived from
monocytes during inﬂammation [14–16].
In immune reactions mature cDCs play a more impor-
tant role as an APC to activate na¨ ıve T cells than pDCs
[12, 17]. In addition, these cells play a central role in
the tumor necrosis factor (TNF) α-dependent experimental
autoimmune arthritis initiated by an irrelevant nonarticular
antigen and no other APC is by itself suﬃcient for breach
self-tolerance mediated by endogenous pathways [8]. Exter-
nal (pathogen-associated molecular patterns) and internal
(alarmins) danger signals or a combination of both leads
to the maturation of cDCs in various inﬂammatory and
infection diseases through membrane receptors, such as
Toll-like receptors (TLR) 1-6, TLR8, and intracytoplasmic
inﬂammasome [8, 12, 17].
On the other hand, engagement of immature cDCs
with na¨ ıve T cells is thought to result in immunological
tolerance. Immature cDCs are characterized by low surface
expression of major histocompatibility complex- (MHC-)
II and costimulatory molecules [9, 17]. Immature cDCs
can drive na¨ ıve T cells to assume Tregs phenotype and/or
promote the function of already existing Tregs as has been
shown in experiments in which antigen was administered
to mice without a concomitant maturation signal. Under
these conditions, antigen accumulated on cDCs in secondary
lymphoid organs and triggered the diﬀerentiation and/or
proliferation of Tregs, resulting in antigen-speciﬁc tolerance
thatcouldpreventorreverseautoimmuneprocesses[18–20].
2.3.PlasmacytoidDendriticCells(pDCs). PDCscanfunction
to limit self-reactivity and consequent pathology [11]. These
cells are also known as interferon- (IFN-) αβ (type I IFN-)
producing cells [11, 21]. Several systemic autoimmune dis-
eases cause a prominent IFN signature (interferon-regulated
genes)intheaﬀectedtargettissuewhichpDCsproduce,such
as rheumatoid arthritis (RA), systemic lupus erythematosus
(SLE), psoriatic arthritis (PsA), systemic sclerosis (SSc), and
Sj¨ ogren’s syndrome (SjS). PDCs are activated to produce
type I IFN by recognition and internalization of immune
complexes consisting of autoantibodies and self-nucleic-
acids, which after endocytosis are recognized through TLR7
and TLR9. On the other hand, pDCs are reported to be key
players in the establishment of oral and transplant tolerance.
Human pDCs activated by the TLR9 DNA ligand CpG-
ODN can induce Tregs [22, 23]. PDCs has the potential
to express indoleamine 2,3-dioxygenase (IDO), an enzyme
that via its products inhibits eﬀector T cell proliferation in
SAIRDs [13, 24]. In the presence of extracellular IDO, T cell
proliferation is compromised, and adaptive diﬀerentiation
Tregs is enhanced although the precise molecular basis for
this eﬀect is still unclear [20, 25, 26].
2.4. Regulatory T Cells (Tregs). Adaptive eﬀector T cell
responses to self and nonself-antigens can be eﬃciently con-
trolled by regulatory T cells belonging to the CD4+CD25+
Treg subset. Tregs are phenotypically heterogeneous and
include both CD4+ and CD8+ T cells, most of which
express forkedhead box p3 (Foxp3) [20, 27]. Tregs can
express anti-inﬂammatory molecules, such as interleukin
(IL)-10, transforming growth factor (TGF)-β and IL-35,
and/or inhibitory receptors, such as cytotoxic T-lymphocyte
antigen 4 (CTLA4), lymphocyte-activation gene 3 (LAG-
3), glucocorticoid-induced tumor necrosis factor receptor
(GITR), CD39, and CD73 [19, 28].
DCs constantly present innocuous self- and nonself-
antigens in a fashion that promotes tolerance, at least in
part, through the control of Tregs [29]. Failure of Tregs
function has been implicated in the development of many
autoimmune processes and, vice versa, cellular therapies
by adoptive transfer of Tregs have shown eﬃcacy in these
disorders [20, 30]. In addition, DCs and Tregs regulate
homeostasis of each other [18–20].
Natural Tregs (nTregs) in thymic tissue develop and
maintain central tolerance during the fetal period. Conven-
tional na¨ ıve T cells can develop to so-called adaptive Tregs
(aTregs) in extrathymic tissues such as secondary lymphoid
organs. This is important, because the autoimmune T cell
have not been completely deleted by the central tolerance
mechanisms. Therefore, aTregs play a complementary role
in the maintenance of the peripheral tolerance by regu-
lating peripheral autoimmune T cells. The role of these
inﬂammation-induced aTregs is not fully understood, but
they seem to limit immunohistopathologic changes by
suppressing autoaggressive responses and/or by promotingClinical and Developmental Immunology 3
restitution of tissue homeostasis (via TGF-β)o rTa n dB
cell memory (via IL-10). Antigen-speciﬁc Tregs can spread
their tolerance-promoting capacity to local DCs and na¨ ıve
T cells through a mechanism called “infectious tolerance”,
which means that tolerant T cells, which are incompletely
stimulated by APCs, induce new na¨ ıve T cells toward a
similar state of tolerance [20, 27, 31].
2.5. Regulatory-B Cells (Bregs). The eﬃcacy of B cell sup-
pression with anti-CD20 therapy such as Rituximab in the
treatment of RA indicates an important role for B cells in
the pathogenesis of RA. In RA, transient B cell depletion
with Rituximab can ameliorate disease for a prolonged
periodbuttypicallynotindeﬁnitely.AutoreactiveBcellshave
been found in bone marrow and peripheral tissues [32].
Anti-TNF agents decreased the peripheral blood memory
and germinal center B cells in RA patients restoring the
e a r l yBc e l lt o l e r a n c ei nR A[ 33]. In addition, B cells are
the main producers of LTα and an important producer of
TNFα in RA synovitis. B cells can also secrete multiple
other cytokines, including IL-1, IL-4, IL-6, IL-7, IL-8, and
IL-12, granulocyte colony-stimulating factor (G-CSF), and
granulocyte-macrophage colony-stimulating factor (GM-
CSF) [34, 35].
On the other hand, B cells are able to suppress autoim-
munity in various animal models through production of IL-
10 and/or TGF-β and by cytokine-independent mechanisms.
Murine models have also revealed a suppressive role for B
lymphocytes. Following stimulation of CD40, B cells inhibit
the induction of arthritis through secretion of IL-10 [36].
In Palmerston North SLE mouse model, regulatory B cells
(Bregs) produce high levels of IL-10 that inhibit production
of IL-12, which leads to diminished inﬂammatory response
to bacterial DNA [37] .Ar o l ef o rB r e g sh a sb e e nr e p o r t e di n
a mouse model of inﬂammatory bowel disease and experi-
mental autoimmune encephalomyelitis [38, 39]. Depending
on the model studies, antigen-speciﬁc autoreactive T and B
cells, DCs, macrophages and/or Tregs are regulated by the
Bregs populations [40]. These observations contribute to the
new and important concept of Bregs [32, 41].
3.AdvancesinMolecularGeneticsand
MolecularDiagnostics
3.1.GeneticsinSystemicAutoimmuneandRheumaticDiseases
(SAIRDs). Advances in the ﬁeld of human genetics have led
to a rapid increase in the number of new disease risk alleles
and loci identiﬁed in SAIRDs patients. In particular, genes
involved in the nuclear factor (NF)-κB pathway and T cell-
D Ci n t e r a c t i o n ss e e mt ob ei n v o l v e di nS A I R D s[ 42–44].
New candidate genes have been reported in RA, and
they include single-nucleotide polymorphisms (SNPs) of IL-
6, signal transducer and activator of transcription (STAT)
4, IL-2RA, CC chemokine ligand (CCL) 21, CD40, CD244,
TNF alpha-induced protein (TNFAIP) 3, sprouty-related
protein with enabled/vasodilator stimulated phosphoprotein
homology 1 domain (SPRED) 2, recombination signal
binding protein for immunoglobulin kappa J region (RBPJ),
CC chemokine receptor (CCR) 6, interferon-regulatory
factor (IRF) 5, PX domain containing serine/threonine
kinase (PXK), cyclin-dependent kinase (CDK) 6, and vita-
min D (Vit.D) Fokl found in genome-wide association
studies (GWAS) [42, 43, 45, 46]. The heritability of RA
has previously been estimated to be about 60%. Recently,
it was reported that the heritabilities of anticitrullinated
protein antibody- (ACPA-) positive and ACPA-negative RA
are rather similar, 68% and 66%, respectively [47–50]. In
particular, human leukocyte antigen- (HLA-) DRB1 and
shared epitope (SE) alleles of it were reported the strong
association with ACPA-positive RA. Apart from perhaps
gender, the main known genetic factor predisposing to RA
is HLA and its contribution to the genetic variation has
previously been estimated to be 37% [51].
In SLE, the IRF5 haplotype has been reported to relate to
an increased production of type I IFN with a concomitantly
increased risk for SLE [52], and a variant of STAT4 increases
the sensitivity to type I IFN in patients with SLE [53]. A
variant of TNFAIP 3, which encodes an ubiquitin-editing
enzyme inhibiting NF-κB-dependent signaling and prevents
inﬂammation, andpolymorphic haplotypesofthehumanT-
lymphotropic virus-1-related endogenous sequence (HRES)
1 long terminal repeat (LTR) have been associated with SLE
[54, 55]. New candidate changes include SNPs in CD40
region, B-lymphoid tyrosine kinase (BLK) gene, vascular
endothelial growth factor (VEGF) receptor 2 gene, and Vit.D
Bsml gene [44, 45].
Polymorphisms in IRF5 are not only associated with RA
and SLE, but also with SSc, inﬂammatory bowel diseases
and multiple sclerosis. An association with STAT4 was ﬁrst
identiﬁed in RA and SLE, but later also found in SSc,
inﬂammatory bowel diseases, type 1 diabetes, psoriasis, and
primary antiphospholipid antibody syndrome [44].
GWASs have disclosed over twenty candidate genes
in PsA, including IL-4, IL-12B, IL-13, IL-23A, IL-23R,
TNFAIP3, TNFAIP3 interacting protein (TNIP) 1, TNF
receptor-associated factor (TRAF) 3 interacting protein (IP)
2, nitric oxide synthase (NOS) 2, v-rel reticuloendotheliosis
viral oncogene homolog (REL), endoplasmic reticulum
aminopeptidase (ERAP) 1, F-box and leucine-rich repeat
protein (FBXL) 19, NF-κ light polypeptide gene enhancer in
B cells inhibitor, alpha (NFKBIA), interferon induced with
helicase C domain (IFIH) 1, IL-28RA, and tyrosine kinase
(TYK) 2 [56, 57].
In SSc, the newly reported candidate genes and risk
loci include CD247, MHC, IRF5, and STAT4 gene regions,
psoriasis susceptibility 1 candidate (PSORS1C) 1, TNIP1,
and putative one close to ras homolog gene family, member
B (RHOB) gene [58].
In SjS, the newly reported candidate genes and risk
loci include early B-cell factor 1 (EBF1) gene, family with
sequence similarity 167 member A (FAM167A)-BLK locus,
TNF superfamily4 gene, HLA-DRB1∗0301, -DQA1∗0501,
and -DQB1∗0201, with SNPs in IL-10 promoter, Fas/FasL,
TGF-β1, and TNFα genes, IRF5 and STAT4 [44].
In addition to the genetic factors also environmental risk
factors and their interactions with the genetic factors con-
tribute to SAIRDs, in particular to RA [42]. One important4 Clinical and Developmental Immunology
environmental risk factor for RA is smoking, which increases
t h eo d d sra t i ot oa b o u t1 . 8[ 59]. SE alleles, lymphoid-speciﬁc
tyrosine phosphatase (LYP)/protein tyrosine phosphatase,
nonreceptor type (PTPN) 22, and cigarette smoking are
risk factors for the development of ACPA positive RA
patients [47, 60]. Further, it has been reported that also the
noninheritedmaternalHLAantigens(NIMA),originallydis-
covered in transplantation immunology [61], containing the
RA-protective DERAA sequence, protect DERAA-negative
children against RA [49, 62].
Ithasbeenrecentlyreportedthatthegenepolymorphism
may not only be associated with the pathogenesis of SAIRDs,
but also with the outcome of the treatment and the
progression of the disease. GWAS and new generation
sequencing disclosed that the response of RA patients to
anti-TNF therapy was associated with ATP-binding cassette,
subfamily A (ABCA) 1, solute carrier family 44 (SLC44A)
1 gene and granzime B SNP were associated with joint
destruction, and protein tyrosine phosphatase, receptor
type, C (PTPRC) locus (rs10919563) and TRAF 6 [63–67].
3.2. MicroRNA. M i c r o R N A sh a v ea t t r a c t e da t t e n t i o na s
potential new biomarkers useful for the diagnosis of early
disease and for the prediction of drug response in SAIRDs.
MicroRNAs form an abundant class of endogenous,
short, noncoding single stranded RNA molecules (19–23
nucleotides) that function as posttranslational regulators
of the expression of genes, such as inﬂammatory cytokines.
M i c r o R N A sw e r eﬁ r s tr e p o r t e di nc a n c e r[ 68]. Recently,
many microRNAs, such as microRNA-16, -146a, -155,
and -223, have been detected in SAIRDs samples, and it is
thought that their expression regulates disease onset/activity
and drug responses [68, 69].
4. New Insightsinto Defective Regulatory
Function in SAIRDs
4.1. Toll-Like Receptor (TLR) and Interferon (IFN) Signature.
In the last decade, a relationship has been described between
TLR and IFN signature. IFN signature is refers to a pattern
of genes regulated by IFN in inﬂamed target tissues. IFN sig-
nature is typical for many SAIRDs, such as RA, SLE, and SSc.
DNA- or RNA-containing immune complexes, formed as a
result of autoantibodies binding antigenic material derived
from apoptotic or necrotic cells, can act as endogenous type
I IFN inducers [70–72]. Prolonged exposure of the immune
system to type I IFN increases the risk for the loss of self-
toleranceandforsubsequentautoimmunereactions.Indeed,
high-serum type I IFN serum levels have been associated
with the development of SAIRDs like SLE [73–75].
PDCs are activated to produce type I IFN when they
recognize immune complexes consisting of autoantibodies
andself-nucleicacids.FollowingFcγRIIa-(CD32-)mediated
internalization, they trigger endosomal TLR7 and TLR9
[76, 77]. PDCs are low in numbers in the blood of SLE
patients, but large amounts of type I IFN are in lupus
produced to serum by the activated pDCs located in the
lymph nodes, skin, and other target organs [74, 78]. Proper
clearance of apoptotic cell rests is normally thought to
prevent harmful exposure of the immune cells to self-
antigens and alarmins and to prevent their autoaggressive
activation [16, 79] .T y p eII F Np l a y sp o w e r f u lr o l e si n
shaping immune responses in SAIRDs by activating
lymphocytes, macrophages, DCs, and natural killer (NK)
cells with the expression of IFN signature [80–82]. If
apoptotic cells are not adequately cleared, condensed, and
fragmented cell rests enter late stage apoptosis or undergo
secondary necrosis, which causes release of nucleosomes,
small nuclear ribonucleoproteins (snRNPs), and DNA, but
also high-mobility group box 1- (HMGB1-) nucleosome
complexes and other signals able to trigger inﬂammation
through TLRs [83–85]. Only extracellular free HMGB1
or nucleosomes alone were not able to activate DCs or
induce cytokine production. HMGB1 was thought to inhibit
and diminish the phagocytosis of apoptotic neutrophils
by macrophage through binding to phosphatidylserine on
the neutrophil membrane and the remains of them might
activate to produce proinﬂammatory mediators through
TLR2 or TLR4 [86]. From studies of lupus-prone mice,
it appears that there are multiple defects in the process
that regulates autoreactive T and B cells, allowing the
maturation of autoreactive B cells. In SLE patients, several
abnormalities interfere with the clearance of apoptotic cell
rests, microparticles and chromatin, such as complement
defects [87] and reduced levels and activity of DNase I in
serum [88]. In lupus-prone mice model, a deﬁciency in a
negative regulator (Tir8/Sigirr) of TLR signaling accelerates
disease progression [89]. Some TLR7-deleted lupus-prone
mice strains have decreased lymphocyte and pDC activation,
decreased serum IgG, and ameliorated autoimmune disease
[90]. TLR7-dependent production of autoantibodies is
decreased in such mouse strains. In contrast, although
CpG-containing DNA, which is a ligand of TLR9, is induced
lupus-like disease, lack of TLR9 in the MRL/lpr mouse
background exacerbated autoantibody production and
disease activity, suggesting that TLR9 protects against lupus
in this model [90, 91]. TLR7 and TLR9 appear to have
diﬀerent roles in the development of murine lupus. Taken
together, these studies suggest TLR9 may either protect or
exacerbateautoimmuneconditionsdependingonthegenetic
background of the lupus-prone mice. Jin et al. demonstrated
that peripheral circulating pDCs in patients with SLE were
functionally abnormal and that they lacked TLR9 [23]. The
role of TLR9 in SLE development is still unclear.
4.2. Th17 and Regulatory T Cells (Tregs). Th 17 cells produce
IL-17 (or actually IL-17A), IL-21 and IL-23 and have been
reported to play a crucial role in inﬂammation in SAIRDs
[92, 93]. A combination of IL-6 and TGF-β is required
for the development of Th 17 cells [92]. Apoptotic bodies
and nucleosomes induce maturation of mouse cDCs to
produce high amounts of IL-6 [79]. On the other hand, the
development and maturation of Tregs is inhibited by IL-6
[15, 94, 95]. IL-6 produced from LPS-treated DC activated
eﬀector T cells and blocked the suppressive eﬀects of Tregs
[94]. In fact, SLE patients have signiﬁcantly lower numbersClinical and Developmental Immunology 5
of CD4+CD25+ Tregs than healthy controls [23, 96]. Anti-
TNF therapy increased Foxp3 mRNA and protein expression
by Tregs and restored their suppressive function [97].
Recently, it was shown that retinoic acid, which binds
the nuclear retinoic acid receptor α (RARα), increases the
expression of Foxp3 and Smad3 in T cells and inhibits
the generation of Th 17 cells [98]. Retinoic acid may be a
candidate drug for RA therapy, because alltrans-retinoic acid
(ATRA) improves clinical symptom in collagen-induced
arthritis mice [99].
4.3. Interleukine (IL)-27 and IL-35. IL-27 and IL-35 are the
dominant anti-inﬂammatory cytokines. IL-27, a member
of the IL-12 family, is a heterodimeric cytokine consisting
of Epstein-Barr virus-induced gene 3 protein (EBI3) and
a unique IL-27-p28 [100]. In collagen-induced mice, IL-
27 reduced disease development and was associated with
downregulation of ex vivo synthesis of IL-17 and IFN-γ
[101].
IL-35, also a member of the IL-12 family, is composed of
EBI3 and p35. IL-35 is thought to be speciﬁcally produced
by Tregs as a novel inhibitory cytokine and is required for
maximal suppressive activity [102].
4.4. Transforming Growth Factor- (TGF-) β. TGF-β has
variant roles due to the inﬂuence of the environments on
its eﬀects. DCs derived from tolerized mice, especially pDCs,
produced increased levels of TGF-β and decreased levels of
IL-6 after stimulation with nucleosomes, which favors the
development of Tregs [79, 103]. TGF-β is unique among
cytokines,becauseitcaninduceFoxp3expressionandaTregs
diﬀerentiation in the absence of DCs [104].
4.5. Follicular Helper CD4 T (TFH)C e l l s . TFH cells are impor-
tant in the regulation of CD4 T cell lineage to Th1, Th2,
Tregs, or Th17 cells [105]. TFH cells expressed transcription
factorBcl6,whichisamasterregulatorofTFH diﬀerentiation.
Bcl6 can antagonize transcription factors important for the
diﬀerentiation of CD4 T cellsto Th1, Th2, or Th17 cells.Bcl6
inhibits Th1 diﬀerentiation by binding to the T-bet gene,
Th2 diﬀerentiation by inhibiting GATA3 protein and Th17
diﬀerentiation by inhibiting RORγt activity and the human
RORγt promoter. Antagonism of Tregs by Bcl6 has not been
reported, but gut Tregs lose Foxp3 and diﬀerentiate into
Bcl6+ TFH cells under inﬂammatory conditions [105]. TFH
cells seem to play important roles in common autoimmune
diseasessuchasRAand SLE[106,107].TFH cellpathwayand
eﬀectormoleculesarepotenttherapeutictargetcandidatesin
SAIRDs.
4.6. B Cells. Natural autoreactive B cells speciﬁc for unmod-
iﬁed parts of self-antigens are normally present. In SLE
patients, this autoreactive B cell fraction is probably larger
than in healthy individuals [108] and a large proportion of
B cells express TLR9, which correlates with high titers of
anti-DNA autoantibodies [109]. In murine B cells, TLR9-
MyD88-dependent signaling is critical for the class switch
to pathogenic IgG antibodies [110]. Thus, at least in B cells,
TLR9 with the BCR signaling appear to activate B cells and
promote autoimmunity.
4.7. Skin Dendritic Cells (Skin DCs). P s o r i a s i si sac o m m o n
chronic inﬂammatory disease of the skin in which the
local activation of autoimmune DCs and T cells induces an
abnormal diﬀerentiation of epidermal keratinocytes [111,
112]. TNF-α and inducible nitric oxide synthase (iNOS)
producing dermal CD11c+ DCs, so called TIP-DCs, are
thought to be the human equivalent of a similar DC subset
necessary for the clearance of some pathogens in mice
[113]. In addition, also pDCs are increased in psoriatic skin
compared with normal skin [114]. Inﬁltration of pDCs into
psoriatic skin and their activation to produce type I IFN
represent key upstream events that initiate the activation of
autoimmune T cells, leading to the formation of the typical
skin lesions [115].
LL37, an endogenous antimicrobial peptide, which is
overexpressed in psoriatic skin, seems to be the key mediator
of pDCs activation in psoriasis. LL37 breaks innate self-
tolerance by forming a complex with self-DNA that is deliv-
ered to and retained within early endocytic compartments
of pDCs to trigger TLR9 to induce type I IFN production,
which then activates IFN signature [116]. LL 37 also binds
self-RNAformingacomplexwhichstimulatespDCsthrough
TLR7 [117]. Self-RNA-LL37 complexes also interact with
TLR8oncDCsandpromotetheirdiﬀerentiationintomature
DCs, which secrete TNF-α and IL-6 [117]. LL37 is released
during skin injury, breaks innate tolerance to self-DNA
and self-RNA so that they can act as “danger signals” that
potently activate innate antiviral-like immune responses
through activation of endosomal TLRs in DCs [116, 117].
Recently, Vit. D3-activated epidermal Langerhans cell
have been shown to induce the development of either
TGF-β-dependent Foxp3+ Treg or IL-10-dependent IL-10+
Treg. This may be the mechanism via which Vit. D3
exerts its immunosuppressive function in inﬂammatory skin
diseases [118]. In addition, Vit. D3 is thought to exert
immunoregulation of DCs and T cells via the upregulation
of CTLA-4.
5. PotentialTreatment OptionsBased on
the Modulation of Immune-Regulatory
Processes(Table 1)
5.1. Glucocorticosteroids-Induced Immune Regulation. Glu-
cocorticosteroids were the ﬁrst immunosuppressants, which
were used in the clinic. The inhibitory eﬀect of glucocorti-
costeroids on the canonical NF-κB pathway probably plays
a key role in the generation of mature DCs and cytotoxic T
cells [119].
Nonspeciﬁc immunosuppressive drugs such as gluco-
corticosteroids have numerous adverse eﬀects and their use
is sometimes limited by a lack of eﬃcacy [120]. Speciﬁc
interference in the production of cytokines, intracellular
signaling pathway, autologous stem-cell transplantation,
gene therapy, immune regulation-induced antigen therapy6 Clinical and Developmental Immunology
Table 1: Potential treatment options for SAIRDs therapy.
Immunogenicity Immunoregultion and tolerance
Cytokine and receptor TNF, TNFR
IL-1 IL-10?
IL-2 IL-27
IL-6, IL-6R IL-35
IL-12
IL-15
IL-17
IL-18
IL-21
IL-23
Type I IFN TGF-β
IFN-γ
BAFF
CD20
CD22
TCR (vaccination) CTLA4-Ig
Intracellular signaling pathway JAK-1
JAK-2
JAK-3
SyK
Stem cells and immune regulation
Autologous stem cell
transplantation
Gene therapy TNFR: Fc
Immune regulation-induced antigen HSPs?
DC therapy Tolerogenic DC
(DC vaccination)
TNF: tumor necrosis factor, TNFR: tumor necrosis factor receptor, IL: interleukine, R: receptor, IFN: interferon, TGF: transforming growth factor, BAFF: B-
cell activating factor, CTLA: cytotoxic T-lymphocyte antigen, TCR: T cell receptor, JAK: Janus kinase, SyK: spleen tyrosine kinase, TNFR: Fc: soluble form of
the tumor necrosis factor receptor, HSPs: heat shock proteins, and DC: dendritic cell.
and DC vaccination are promising treatment targets for
induction of SAIRDs at present.
5.2. Anticytokine Therapy. Therapies with biological agents
toattainanti-inﬂammatoryandimmunosuppressiveactions,
using drugs such as anticytokines and cytokine receptors,
have remarkably improved the results of the treatments for
many SAIRDs patients [5, 12]. Successful identiﬁcation of
biological targets and their therapeutic translation (anti-
TNF, anti-IL-6 receptor, anti-CD20, CTLA4-Ig, and anti-
IL-1) will help many patients refractory to conventional
intervention for RA, PsA, Crohn’s disease, SLE, and so on
[121].Concentrationsofproinﬂammatorycytokines,suchas
TNF-α,IL-1,IL-6,IL-12,IL-15,IL-18,typeIIFN,IFN-γ,and
B cell stimulating agents, are increased in SAIRDs. They play
important roles in the inﬂammatory processes that lead to
tissue and organ damage [122].
5.3. Tumor Necrosis Factor (TNF). TNF-α stimulates migra-
tion of mature cDCs to the draining lymph nodes. TNF-α
blockade can prevent this inﬂux of antigen-presenting DCs
to secondary lymphatic tissue, which is an important step for
the activation of T cell responses [123]. The TNF blockers
have been successfully used in the management of RA, PsA,
and Crohn’s disease; however, they can in some cases induce
autoantibodies and lupus-like syndromes. Thus, their use
in SLE is controversial [122, 124–126]. In SLE, the use of
anti-TNF blockers has been associated with polyarthritis,
cutaneous manifestations, disease activity, proteinuria, and
nephritis but also severe infusion reactions [127,128].In SjS,
anti-TNFblockershavenotshownanyclinicaleﬃcacy[129].
5.4. Interleukine- (IL-)1 and IL-18. Blockade of IL-1 and IL-
18 has raised interest in human SLE. The results of twoClinical and Developmental Immunology 7
small, open-label trials of the recombinant human IL-1
receptor antagonist anakinra in SLE have been published,
both of which reported beneﬁcial eﬀects [7, 130]. In RA,
the eﬀectiveness of IL-1 receptor antagonist therapy is clearly
lower than that of the TNF blockers [131] .I L - 1 8a c t sa sa
chemoattractant stimulating the migration of pDCs to the
glomeruli in the kidney [78] so its blockade might be a good
therapeutic target.
5.5. Interleukine (IL)-6. IL-6 is a pleiotropic cytokine that is
overexpressed in patients with several SAIRDs. In contrast
to other cytokines, IL-6 can bind to a soluble IL-6 receptor
(sIL-6R) without being inhibited. On the contrary, this IL-
6/sIL-6R complex can bind to IL-6R-negative cells via a
nonligand binding but signal transducing pg130 component
of the receptor complex. Therefore, antibodies against IL-6R
inhibit such IL-6 actions. Accordingly, good clinical results
werereportedontheuseofahumanizedantibodyagainstIL-
6R, tocilizumab, in RA and juvenile idiopathic arthritis (JIA)
[132]. An open-label study conducted using tocilizumab in
SLE reported moderate eﬀectiveness [133]. Some phase II
trials of IL-6 blocking monoclonal antibodies are ongoing in
SLE [134].
5.6. Interleukine (IL)-10. Disease activity in many SAIRDs
h a sb e e nc o n s i d e r e dt ob ed r i v e nb ya ni m b a l a n c eb e t w e e n
proinﬂammatory and anti-inﬂammatory cytokines. IL-10
is a powerful anti-inﬂammatory cytokine, which can be
produced by both leukocytes and structural cells within
tissues, being produced in particular by Tregs in vivo [20,
135].However,highserumlevelsofIL-10havebeenreported
in patients with SLE and they correlated positively with the
disease activity [136]. Therefore, somewhat paradoxically,
in an open-label pilot study, a single injection of a mouse
anti-IL-10 monoclonal antibody, given to a small group of
active SLE patients, seemed to have beneﬁcial clinical eﬀects
[137]. It was concluded that it was beneﬁcial to boost the
cell-mediated immune responses in SLE by inhibiting IL-
10, because IL-10 impairs antigen presentation and Th1
lymphocyte activation.
5.7. Interleukine- (IL-) 17 and Others. IL-17 (or actually IL-
17A) has been discovered to be a powerful proinﬂammatory
cytokine and the recent detection of a Th17 T-helper cell
subset that secretes it has focused attention on the role of
IL-17 and Th17 cells in SAIRDs, in particular RA, PsA,
multiple sclerosis and Crohn’s disease, which are considered
to represent Th17-related diseases. Several therapeutically
interesting compounds have been reported, including anti-
IL-17A agent (AIN 457 and LU2439821), anti-IL-17 receptor
(AMG827) or anti-IL-17A/F receptor [92, 93, 138].
IL-12 and IL-23, which belongs to the IL-12 family, are
important regulators of Th17 lymphocytes and dominant
candidates for the treatment of SAIRDs with IL-17 involve-
ment [139–141]. Anti-IL-12/23p40 agents (CNTO1275:
Ustekinumab and ABT-874) are directed against both IL-
12 and IL-23. An ustekinumab study is ongoing in phase
III in PsA [142]. In addition, IL-21 and IL-22 are attractive
therapeutic targets as cytokines related to Th17 cells [7, 122,
143]. IL-27 and IL-35 also belong to the IL-12 family and
may be candidate tools to inhibit Th17 cells in the future
[101, 102].
5.8. B Cell Related Cytokine. B-cell activating factor (BAFF,
also known as B-lymphocyte stimulator (BLyS) and TNF
ligand superfamily member 13B) promotes B-cell survival
and autoantibody production. BAFF blocker (Belimumab)
seems to be close to the public authority approval as
they have been completed in large, double-blind, placebo-
controlled studies of patients with active SLE in a phase III
study[7,144],completedinphaseIIstudyinRA[145].Anti-
CD22 monoclonal antibody (Epratuzumab) has ﬁnished a
phase III trial in SLE [146].
Recent experimental and clinical evidence obtained in
SSc-like mouse models and SSc patients suggests a role for B
cells in the development of inﬂammation and ﬁbrosis char-
acteristic for this disease [147]. Antihuman CD20 antibody,
that has been reported to be eﬀective in the treatment of
RA (Rituximab and Ofatumumab in phase III), had some
beneﬁcial eﬀects also on skin ﬁbrosis and lung involvement
in SSc patients [148, 149]. In SjS patients, a phase II trial
of Rituximab has been ﬁnished and Belimumab prepared
[150, 151]. BAFF blocker as well as anti-CD20 blocker is one
of potential drugs in the treatment of SAIRDs.
5.9. Intracellular Signaling Pathway. Among various signal-
ing molecules activated by cytokine-receptor interaction,
the small molecules targeting in particular Janus kinase-
(JAK-) STAT pathway form attractive candidate drugs in the
treatment of SAIRDs. Inhibitors of various JAK molecules
(JAK-1/2, JAK-2, JAK-3) might be useful in the treatment
of SAIRDs [5, 152, 153]. Some trials of JAK-3 inhibitor
in patients with RA (CP690,550 in phase III), PsA and
inﬂammatory bowel diseases have already been published
[153–156]. JAK-3 is critical for signal transduction for IL-2,
IL-4,IL-7,IL-9,IL-15,andIL-21,andaselectiveinhibitionof
JAK-3 has immunomodulatory eﬀects, which aﬀect T cells,
B cells, macrophages, and NK cells, without signiﬁcantly
aﬀecting other organ systems. JAK inhibitors may ﬁnd
clinical applications in SAIRDs in the near future.
Spleen tyrosine kinase (SyK), which is another nonre-
ceptor tyrosine kinase, could to be one of treatment targets
in SAIRDs. A phase III trial of SyK inhibitor (R788) in RA
(OSKIRA trial) is ongoing [157].
In addition to monoclonal antibodies and receptor
fusion proteins, other alternative approaches to neutralize
inﬂammatory cytokines are being developed in experimental
models. These include vaccinations against cytokines, which
have been found to be important in the disease mechanisms
[158]andadministrationofsmallinterferingRNAs(siRNAs)
that target the messenger RNAs encoding key cytokines
[3]. Another approach is to use small molecules to block
certain cytokine pathways. For example, T-cell receptor
(TCR) vaccinations and epitope-mimetic peptides (e.g., A9
in collagen-induced arthritis) are also in experimental use
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5.10. Stem Cells and Immune Regulation. At ﬁrst, most of
the experience with autologous stem-cell transplantation in
arthritis derived from studies with SSc, multiple sclerosis,
and systemic JIA that were refractory to conventional
therapies. Recently, also patients of RA and SLE have been
treated with autologous hematopoietic stem cells, but their
eﬀect was limited in RA. Phase II trials of autologous stem-
cell transplantation are ongoing in SLE and SSc [161]. In this
procedure, autologous hematopoietic stem cells are collected
and stored but transferred back to the donor after the
remainingbonemarrowandbloodcellshavebeendestroyed.
The autotransplant then reconstitutes the hematopoietic and
immune system and is hoped to restore the self-tolerance.
Indeed, a small study reported that Tregs were restored
by transplantation of autologous hematopoietic stem cells
[162]. Autologous stem-cell transplantation therapy has
potential in the treatment of also other SAIRDs in the future.
5.11. Gene Therapy. Some small clinical trials of the gene
therapy have been done in RA in vivo and ex vivo
[163]. Local viral gene therapies by tgACC 94, which is
a recombinant adeno-associated virus serotype 2 vector
genetically engineered to contain the cDNA for a human
TNFR-immunoglobulin (IgG1) Fc fusion gene, are going
on phase I in RA and phase II in PsA [164]. However,
several reasons such as the limitation of eﬃcacy and logistic
and ﬁnancial issues have deterred to step up the next
trial phases. Technically insertions, alterations, or removals
of genes can be done, but gene therapy is diﬃcult to
apply in polygenic diseases. Generation of an appropriate
gene construct is already challenging but gene transfer and
host immune responses against the gene therapy vectors
form additional barriers to clinical applications. Due to the
haphazard and random location of the gene in the host
genome, insertional mutagenesis, and cancer development
pose a potential threat. Further studies are needed for the
gene therapy with new techniques such as siRNA [163, 165].
5.12. Immune Regulation Induced by Antigens. Secondary
antigens (T-cell epitopes) that are involved in the ampli-
ﬁcation and maintenance of immune-inﬂammation, but
independent of the initial and evasive “factor X” triggering
the SAIRDs, might have therapeutic potential. Heat shock
proteins (HSPs) are often targeted by proinﬂammatory T-
cell responses in arthritis and induction of mucosal tolerance
induced against their proinﬂammatory, immunodominant
epitopes could provide a means to alleviate autoimmune
inﬂammation in RA [166]. The dnaJP protein, which
encodes a 15mer peptide (dnaJP1) derived from the bacterial
HSP, was administered to induce immune tolerance in RA
patients in a small trial study [167].
5.13. DC Therapy. Maintenance of the immature, immu-
noincompetent state of DCs, especially after in vivo delivery,
remains a challenging but also promising task. For progress
in this ﬁeld, the methods for generation and delivery of
tolerogenic or vaccinated DCs have ﬁrst to be standardized.
Recently, chronic stimulation of pDCs with self-
nucleosomes through TLR7 and TLR9 to produce type I
IFN was reported to reduce therapeutic eﬀects of glucocor-
ticosteroids in SLE [90, 168]. Vice versa, inhibition of TLR7
improveddiseasemanifestationsinalupusmousemodelbut
not TLR9 [90, 91, 95].
The endogenous proapoptotic agents and the death
receptors involved in the maturation of DCs and acti-
vation of speciﬁc T cell subsets, such as Th 17 cells,
may become novel targets for the individualized, disease
process-speciﬁc treatments of SAIRDs. Human monocyte-
derived tolerogenic DCs, generated with dexamethasone
and Vit. D3, maintained their tolerogenic function upon
activation with lipopolysaccharide (LPS-tolerogenic DCs),
while acquiring the ability to present human type II collagen
(autoantigen) and migrate in response to CCR 7 ligand, CCL
19 [169, 170]. Vaccination with autologous tolerogenic DCs
(RHEUMAVAX) is in preliminary phase I human trial [171].
6. Conclusion
The pathogenesis and mechanism of SAIRDs are not fully
understood. However, various molecules, signal transduc-
tion,andimmune eﬀectorpathwaysabletoregulateimmune
regulation and tolerance are being increasingly revealed. For
the generation of new drugs and therapies, it is important
to know molecules and understand mechanisms responsible
for the maintenance, failure, and restoration of tolerance in
SAIRDs. Molecularly targeted and highly speciﬁc biologic
agents have caused a paradigm shift of the treatment. How-
ever, in spite of top-of-the-line drugs applied according to
current management strategies, some 20%–30% the patients
do not respond adequately. Further, there are still several
issues to be resolved, also with the currently used drugs, such
as severe adverse events and the high cost although small
chemical molecules, such as JAK inhibitors, might oﬀer low
costoptionspossibletoadministereasilyperos.Itisexpected
thatthedevelopmentleadstonewdrugswhichareabletore-
establish autoimmune regulation and tolerance in SAIRDs,
drugs, which are more eﬀective and tailored based on genetic
polymorphism and at the same time safer, low cost, and easy
to administer.
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